Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.62 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901303 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL14929176 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30534760 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28746706 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL4083531 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL10072865 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL24780347 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL12143854 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL22236624 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL21055679 | 1.00 | SLC28A1 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011028-A | Method for efficiently preparing various substituted chiral phosphoramides | 上海交通大学 | 2026-05-12 | — | — | CN | claimed |
| US-12577270-B2 | 2′,3′-diacetyluridine substituted with acetoacetyl at the 5′ position | PHARMA CINQ, LLC (US) | 2026-03-17 | — | — | US | claimed |
| CN-119613475-A | Preparation method of copper-catalyzed asymmetric synthesis nucleoside prodrug intermediate or prodrug based on P (V) precursor | 上海交通大学 | 2025-03-14 | — | — | CN | claimed |
| US-20230357304-A1 | 2′,3′-Diacetyluridine Substituted With Acetoacetyl at the 5′ Position | WELLSTAT THERAPEUTICS CORPORATION | 2023-11-09 | — | — | US | claimed |
| EP-4210709-A1 | 2',3'-DIACETYLURIDINE SUBSTITUTED WITH ACETOACETYL AT THE 5' POSITION | Wellstat Therapeutics Corporation (US) | 2023-07-19 | — | — | EP | claimed |
| CN-116157133-A | 2',3' -diacetyluridine substituted with acetoacetyl group at 5' position | 维尔斯达医疗公司 | 2023-05-23 | — | — | CN | claimed |
| JP-60066953-A | — | — | None | — | — | JP | disclosed |
| CN-122011028-A | Method for efficiently preparing various substituted chiral phosphoramides | 上海交通大学 | 2026-05-12 | — | — | CN | disclosed |
| US-12577270-B2 | 2′,3′-diacetyluridine substituted with acetoacetyl at the 5′ position | PHARMA CINQ, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260055125-A1 | LIGAND-ASSISTED DEOXYGENATION OF PHOSPHATES TO FORM NITROGEN-CONTAINING PHOSPHORUS(V) PRECURSORS AND THEIR SUBSEQUENT CONVERSION TO VARIOUS OXYPHOSPHORUS COMPOUNDS | UNIV DRESDEN TECH (DE) | 2026-02-26 | — | — | US | disclosed |
| CN-119613475-A | Preparation method of copper-catalyzed asymmetric synthesis nucleoside prodrug intermediate or prodrug based on P (V) precursor | 上海交通大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-119528981-A | Chiral phosphonate compound and derivative thereof, preparation method, pesticide bacteriostat and application | 贵州大学 | 2025-02-28 | — | — | CN | disclosed |
| US-12054768-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-06 | — | — | US | disclosed |
| EP-0111299-B1 | FLUORINE-CONTAINING URIDINE DERIVATIVE AND PREPARATION AND USE THEREOF | Daikin Kogyo Co., Ltd. (JP) | 1986-04-02 | — | — | EP | disclosed |
| US-4542209-A | Fluorine-containing uridine derivative and preparation and use thereof | DAIKIN KOGYO CO., LTD. (JP) | 1985-09-17 | — | — | US | disclosed |
| US-4542209-A | Fluorine-containing uridine derivative and preparation and use thereof | DAIKIN KOGYO CO., LTD. (JP) | 1985-09-17 | — | — | US | disclosed |
| JP-S6066953-A | BITTERING AGENT | YAMASA SHOYU CO LTD | 1985-04-17 | — | — | JP | disclosed |
| EP-0111299-A1 | Fluorine-containing uridine derivative and preparation and use thereof | Daikin Kogyo Co., Ltd. (JP) | 1984-06-20 | — | — | EP | disclosed |
| EP-0111299-A1 | Fluorine-containing uridine derivative and preparation and use thereof | Daikin Kogyo Co., Ltd. (JP) | 1984-06-20 | — | — | EP | disclosed |
| US-4056673-A | VIRICIDE, ANTINEOPLASTIC | HOFFMANN-LA ROCHE INC. (US) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055125-A1 | LIGAND-ASSISTED DEOXYGENATION OF PHOSPHATES TO FORM NITROGEN-CONTAINING PHOSPHORUS(V) PRECURSORS AND THEIR SUBSEQUENT CONVERSION TO VARIOUS OXYPHOSPHORUS COMPOUNDS | CA2, CA4, CA6 | SLC28A1 462/4885SLC28A2 406/4885SLC29A1 254/4885 |
| US-12577270-B2 | 2′,3′-diacetyluridine substituted with acetoacetyl at the 5′ position | UQCRC2, ACAT1, ACAA2 | SLC28A1 441/4885SLC28A2 268/4885SLC29A1 307/4885 |
| US-20230357304-A1 | 2′,3′-Diacetyluridine Substituted With Acetoacetyl at the 5′ Position | ACAT1, ACADVL, ACAA2 | SLC28A1 1416/4885SLC28A2 1134/4885SLC29A1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.